ImmunoCellular Therapeutics, Ltd.
(NYSE Amex Equities : IMUC)

( )
IMUC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading IMUC News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.31%72.131.0%$655.07m
AMGNAmgen Inc.
0.63%155.770.8%$509.15m
CELGCelgene Corporation
0.24%115.221.0%$465.18m
ARIAARIAD Pharmaceuticals, Inc.
0.23%23.7016.4%$416.43m
BIIBBiogen Inc.
0.21%283.611.0%$405.76m
ALXNAlexion Pharmaceuticals, Inc.
0.42%135.872.5%$385.05m
REGNRegeneron Pharmaceuticals, Inc.
-0.08%362.952.5%$365.07m
ILMNIllumina, Inc.
0.47%161.233.8%$225.12m
CLVSClovis Oncology, Inc.
0.64%56.6217.9%$166.73m
VRTXVertex Pharmaceuticals Incorporated
1.19%82.522.1%$152.50m
INCYIncyte Corporation
1.28%115.092.2%$149.42m
SRPTSarepta Therapeutics, Inc.
-0.42%35.9816.8%$110.90m
ACADACADIA Pharmaceuticals Inc.
3.06%32.3118.3%$110.16m
IONSIonis Pharmaceuticals, Inc.
1.12%47.148.9%$110.11m
TSROTESARO, Inc.
-1.32%149.2615.0%$109.40m

Company Profile

ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that develops immune-based therapies for the treatment of brain and other cancers. ImmunoCellular's pipeline includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.